Online citations, reference lists, and bibliographies.

Metabolic Tumor Volume As A Prognostic Imaging-based Biomarker For Head-and-neck Cancer: Pilot Results From Radiation Therapy Oncology Group Protocol 0522.

David L. Schwartz, Jonathan Harris, Min Yao, David I. Rosenthal, Adam Opanowski, Anthony Levering, Kian K. Ang, Andy M Trotti, Adam S Garden, Christopher Uwe Jones, Paul M. Harari, Robert L. Foote, John Michael Holland, Qiang Zhang, Quynh-Thu Le
Published 2015 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE To evaluate candidate fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging biomarkers for head-and-neck chemoradiotherapy outcomes in the cooperative group trial setting. METHODS AND MATERIALS Radiation Therapy Oncology Group (RTOG) protocol 0522 patients consenting to a secondary FDG-PET/CT substudy were serially imaged at baseline and 8 weeks after radiation. Maximum standardized uptake value (SUVmax), SUV peak (mean SUV within a 1-cm sphere centered on SUVmax), and metabolic tumor volume (MTV) using 40% of SUVmax as threshold were obtained from primary tumor and involved nodes. RESULTS Of 940 patients entered onto RTOG 0522, 74 were analyzable for this substudy. Neither high baseline SUVmax nor SUVpeak from primary or nodal disease were associated with poor treatment outcomes. However, primary tumor MTV above the cohort median was associated with worse local-regional control (hazard ratio 4.01, 95% confidence interval 1.28-12.52, P=.02) and progression-free survival (hazard ratio 2.34, 95% confidence interval 1.02-5.37, P=.05). Although MTV and T stage seemed to correlate (mean MTV 6.4, 13.2, and 26.8 for T2, T3, and T4 tumors, respectively), MTV remained a strong independent prognostic factor for progression-free survival in bivariate analysis that included T stage. Primary MTV remained prognostic in p16-associated oropharyngeal cancer cases, although sample size was limited. CONCLUSION High baseline primary tumor MTV was associated with worse treatment outcomes in this limited patient subset of RTOG 0522. Additional confirmatory work will be required to validate primary tumor MTV as a prognostic imaging biomarker for patient stratification in future trials.
This paper references
10.1158/1078-0432.CCR-08-3290
Metabolic Tumor Volume of [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Short-Term Outcome to Radiotherapy With or Without Chemotherapy in Pharyngeal Cancer
Man Ki Chung (2009)
A New Look at the Statistical Model Identification
HIROTUGU AI AIKE
10.1001/archotol.130.12.1361
FDG-PET prediction of head and neck squamous cell cancer outcomes.
David L. Schwartz (2004)
A possible prognostic factor in head and neck cancer
W Halfpenny (2002)
10.1198/tech.2003.s768
The Statistical Analysis of Failure Time Data
Laurence L. George (2003)
10.1016/j.ijrobp.2010.01.057
Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer.
James D Murphy (2011)
10.1002/SIM.5511
Contrasting treatment‐specific survival using double‐robust estimators
KyungMann Kim (2012)
10.1080/00401706.1982.10487769
The Statistical Analysis of Failure Time Data
John P. Klein (1982)
10.3310/hta11440
Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.
Karen M Facey (2007)
10.1038/sj.bjc.6600114
FDG–PET. A possible prognostic factor in head and neck cancer
Wayne Halfpenny (2002)
10.1200/JCO.2004.08.120
Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.
Gerald Antoch (2004)
10.1007/978-1-4612-4380-9_25
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
10.1038/sj.bjc.6602464
Impact of combined 18F-FDG PET/CT in head and neck tumours
Rizwan Syed (2005)
CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma
Dl Schwartz (2005)
Regression Models and Life-Tables
D.
10.1016/j.ijrobp.2009.08.063
Prospective imaging assessment of mortality risk after head-and-neck radiotherapy.
Benjamin J. Moeller (2010)
10.2307/2983027
Multiple Imputation for Nonresponse in Surveys
Roger A. Sugden (1988)
10.1016/j.ijrobp.2004.01.040
The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma.
Min Yao (2004)
10.1016/j.oraloncology.2011.11.001
Prognostic significance of radiologically determined neck node volume in head and neck cancer: a systematic review.
Wouter L Lodder (2012)
Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006.
Johannes G Czernin (2007)
18F-fluorodeox- yglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: A meta-analysis
Pa Kyzas (2008)
10.1148/radiol.2311030271
Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion.
Heiko Schöder (2004)
10.1016/S0360-3016(00)01559-5
The relation of CT-determined tumor parameters and local and regional outcome of tonsillar cancer after definitive radiation treatment.
Robert Hermans (2001)
10.1200/JCO.2008.19.3300
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer.
Benjamin J. Moeller (2009)
10.1080/10629360600810434
Fully conditional specification in multivariate imputation
Stef van Buuren (2006)
10.1016/j.ijrobp.2004.03.040
FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma.
David L. Schwartz (2005)
10.1016/J.YPED.2010.12.093
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
James A. Stockman (2012)
10.1200/JCO.20.5.1398
Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy.
Abdelkarim Said Allal (2002)
10.1016/j.radonc.2004.10.005
Is there any future in radiotherapy planning without the use of PET: unraveling the myth...
Vincent Grégoire (2004)
10.1200/JCO.2004.00.3335
Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis.
Paul Maurice Weinberger (2006)
10.1016/j.ijrobp.2011.10.023
Validation that metabolic tumor volume predicts outcome in head-and-neck cancer.
Chad Tang (2012)
Head and neck cancer: Clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004;231:65-72
H Schoder (2004)
10.1093/jnci/djn125
18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis.
Panayiotis A. Kyzas (2008)
10.1007/s00259-007-0564-5
TNM staging with FDG-PET/CT in patients with primary head and neck cancer
Patrick Veit-Haibach (2007)
10.1016/j.ijrobp.2008.10.060
Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer.
Trang H. La (2009)



This paper is referenced by
10.1002/hed.24454
Prognostic value of midtreatment FDG-PET in oropharyngeal cancer.
Erqi L Pollom (2016)
10.1016/j.ijrobp.2019.03.036
Integrating Tumor and Nodal Imaging Characteristics at Baseline and Mid-Treatment Computed Tomography Scans to Predict Distant Metastasis in Oropharyngeal Cancer Treated With Concurrent Chemoradiotherapy.
Jia Wu (2019)
10.18632/oncotarget.11574
Prognostic value of metabolic parameters on preoperative 18F-Fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III gastric cancer
Sae Jung Na (2016)
10.2399/jmu.2018001008
Predictive and prognostic values of pretreatment functional imaging-based biomarkers in advanced-stage laryngeal cancer
Görkem Eskiizmir (2018)
10.21037/TCR.2020.03.16
Predicting response to radiotherapy in tumors with PET/CT: when and how?
Lifang Shen (2020)
10.4274/mirt.94914
The Correlation Between Pre-treatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Parameters and Clinical Prognostic Factors in Pediatric Hodgkin Lymphoma
Ebru Tatcı (2017)
10.1002/hed.25337
Pretreatment metabolic tumor volume as a prognostic factor in HPV‐associated oropharyngeal cancer in the context of AJCC 8th edition staging
John M Floberg (2018)
10.1007/s00259-018-4134-9
PET-based prognostic survival model after radiotherapy for head and neck cancer
Joël Castelli (2018)
10.3389/fonc.2019.01118
Predictive Values of MRI and PET Derived Quantitative Parameters for Patterns of Failure in Both p16+ and p16– High Risk Head and Neck Cancer
Yue Cao (2019)
10.1002/hed.25932
Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy.
Jason Chia-Hsun Hsieh (2019)
10.1002/hed.25505
Volumetric 18F‐FDG‐PET parameters as predictors of locoregional failure in low‐risk HPV‐related oropharyngeal cancer after definitive chemoradiation therapy
Thong Chotchutipan (2019)
10.1016/j.semradonc.2019.02.006
Functional Adaptation in Radiation Therapy.
Martha M. Matuszak (2019)
10.1097/MNM.0000000000000641
Effect of different segmentation algorithms on metabolic tumor volume measured on 18F-FDG PET/CT of cervical primary squamous cell carcinoma
Weina Xu (2017)
10.1016/j.hoc.2015.07.008
Radiation Oncology--New Approaches in Squamous Cell Cancer of the Head and Neck.
Danielle N Margalit (2015)
10.1007/s12032-019-1318-5
nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma
Kai C. C. Johnson (2019)
10.1007/s00259-018-4065-5
What is the prognostic impact of FDG PET in locally advanced head and neck squamous cell carcinoma treated with concomitant chemo-radiotherapy? A systematic review and meta-analysis
Pierluigi Bonomo (2018)
10.18632/oncotarget.25030
Use of baseline 18F-FDG PET scan to identify initial sub-volumes with local failure after concomitant radio-chemotherapy in head and neck cancer
F. Legot (2018)
10.1016/j.oraloncology.2015.09.001
Pre-treatment tumor-specific growth rate as a temporal biomarker that predicts treatment failure and improves risk stratification for oropharyngeal cancer.
Colin T. Murphy (2015)
10.1016/j.cpet.2016.02.002
PET/CT in Head-neck Malignancies: The Implications for Personalized Clinical Practice.
Heidi R Wassef (2016)
10.1002/lary.27173
FDG-PET metabolic tumor parameters for the reirradiation of recurrent head and neck cancer.
Maria Agudelo Velez (2018)
10.1007/s00259-017-3836-8
The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer
Ka-Rham Kim (2017)
10.1007/s11307-019-01351-4
PET/CT-Based Response Evaluation in Cancer—a Systematic Review of Design Issues
Oke Gerke (2019)
10.3390/medicina54060107
Use of 18F-FDG PET/CT Imaging for Radiotherapy Target Volume Delineation after Induction Chemotherapy and for Prognosis of Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Viktoras Rudžianskas (2018)
10.1038/s41598-019-45462-y
Predictive Value of Pretherapeutic Maximum Standardized Uptake Value (Suvmax) In Laryngeal and Hypopharyngeal Cancer
Jonas Werner (2019)
10.1097/RLU.0000000000001614
Metabolic Tumor Volume and Total Lesion Glycolysis in Oropharyngeal Cancer Treated With Definitive Radiotherapy: Which Threshold Is the Best Predictor of Local Control?
Joël Castelli (2017)
10.1002/hed.24465
Prognostic value of FDG-PET volumetric parameters in patients with p16-positive oropharyngeal squamous cell carcinoma who received curative resection followed by postoperative radiotherapy or chemoradiotherapy.
Kyung Hwan Kim (2016)
Comparison of CT based and integrated f 18 FDG pet CT scan based gross tumour volume in head and neck cancers and evaluation of the different segmentation method for delineation of the target on pet scan.
Gayathri Gopu (2016)
10.1259/BJR.20160217
Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist.
Jon Cacicedo (2016)
10.1002/hed.25429
Prognostic significance of pretreatment 18F‐fluorodeoxyglucose positron emission tomography evaluation using metabolic tumor volume of the primary tumor and lymph nodes in advanced hypopharyngeal cancer
Eiichiro Okazaki (2019)
10.1016/j.ijrobp.2017.12.269
Adaptive Boost Target Definition in High-Risk Head and Neck Cancer Based on Multi-imaging Risk Biomarkers.
Feifei Teng (2018)
10.1016/j.ejca.2017.01.018
A PET-based nomogram for oropharyngeal cancers.
Joël Castelli (2017)
10.1088/1361-6560/aaa175
Optimal transformations leading to normal distributions of positron emission tomography standardized uptake values.
Matthew Scarpelli (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar